COVID-19 Candidates Information Updated: 03/17/2021

Manufacturer Doses Handling + Efficacy Timeline of Fed Govt Technology/Type Requirements Administration Development Contract Pfizer/BioNTech mRNA vaccine Distributed at -80 Original Mix with Reported 95% EUA granted 100 mil to -60 ᵒC and can for 5 diluent on site. efficacy (Press Dec. 11, 2020. doses in 2 dose series 21 be stored at this doses/vial in Release) original days apart temperature until protocol. Once one vial purchase. expiry date. Changed to 6 removed from Efficacy reduced began Dec. 14, doses per vial. pizza box, the towards UK and 2020 Additional May be stored entire box is South African 100 mil -25ᵒC to -15ᵒC FDA advises to considered as Variants (Press January 2021 purchased for two weeks use all available having started Release). Pfizer completed Dec.23, cumulatively with doses, now to thaw. enrolling children 2020 to one return to -80 considered 6 ages 12+ in Phase have by to -60 ᵒC. (may be able to May be III trial. They July 2021. get 7). transported at hope for data by Stable for 5 hours: -25ᵒC to - summer 2021 120 2-8 ᵒC Minimum order: 15ᵒC. (here). million 1024 doses total by Stable for up to (based on 5 Phase I clinical the end of 30 days in doses per vial) trial to March shipping box if dry investigate the 2021 and ice is maintained safety and another and 5 days after efficacy of a 3rd 180 at 2-8 ᵒC for a booster shot of million by total of 35 days. Pfizer COVID-19 the end of vaccine began July. February 25, 2021 (here).

Recruiting pregnant women for a Phase II/III trial (here). 1

Moderna mRNA vaccine Lasts for 6 10 doses/vial No dilution or Reported 94.1% EUA granted 100 mil months at -25ᵒC special efficacy (Press Dec. 18, 2020. doses in 2 dose series 28 to -15ᵒC Minimum order handling on Release) original days apart is 10 vials: 100 site. Vaccination purchase. Can be stored for doses Efficacy reduced began Dec. 30 days 2-8 ᵒC towards UK and 21,2020. Additional prior to first use South African 100 mil Variants (Press March 10, 2021 purchased Good for 12 hours Release). began trial to on Dec. at 8-25ᵒC evaluate a 11, 2020 COVID-19 to have by Vaccine is viable vaccine booster July 2021. for 6 hours once for the South vial is pierced African variant Total 100 (Press Release) (here). million by the end of March 15, 2021 March began Phase I 2021 and trial for next another generation 100 COVID-19 million by vaccine mRNA- the end of 1283 (here). July 2021.

March 16, 2021 first patients doses in Phase II/III enrolling children aged 6 months to 12 years (here). Janssen (+ 1 dose Storage at 2-8 ᵒC 5 dose/vial of No Reported 66% EUA granted 20 million Johnson & Adenovirus for up to three 0.5mL dose preservative in efficacy globally February 27, by the end Johnson) Vector based months vial, no and 72% within 2021. of March, vaccine 10 vials per reconstitution the US. 85% another carton, 48 effective in 100

2

After first use cartons per required at preventing severe Vaccination million by lasts for 6 hours shipper = 2400 site. . These began March 1, the end of at 2-8 ᵒC doses per lower efficacies 2021. July shipper Do not are attributed to Expected to vigorously the study being remain stable for Minimum order shake, but done while SARS- up to two years at 100 doses. otherwise can CoV-2 variants -20° C. handle driving were on bumpy predominant in roads or being study areas. jostled.

AstraZeneca and Adenovirus Storage at 2-8 ᵒC No dilution or 90% reported for A phase III trial in 300 mil Oxford Vector based, 2 for 6 months reconstitution the group who the US of 30,000 doses doses received a half participants is After first dose and then a expected to yield puncture, store full dose. clarifying results up to 6 hours at on the best dose room 60% reported for regimen. temperature or the group who up to 48 hours at received 2 full AstraZeneca 2-8 ᵒC doses (read more expects data here) from US Phase III clinical trial to be Feb 2, 2021: available soon reported single and file for EUA dose 76% efficacy in April. and after second dose given 12 Approved in UK, weeks later was Argentina, Brazil, 82.4%. Data also India, and suggests reduced COVAX. Use transmission in suspended in addition to Germany, France, prevention of Italy, Norway, symptoms (here) Denmark,

3

Iceland, Netherlands. NOVAVAX Protein-based Storage at 2-8 ᵒC 10 doses/vial Co-formulated Final analysis of Phase III trial in 110 vaccine candidate Handling at room with adjuvant. UK trial confirms US began Dec. million containing temp: 25 ᵒC Minimum order: No mixing 96.4% efficacy 28, 2020 with purchased derived Very stable under assume 100 required. against original goal of enrolling by the US from the stress conditions, doses COVID-19 and 30,000 spike will utilize 86.3% against participants (S) protein. standard cold B.117 (UK) strain. (here). chain Complete analysis 2 dose series from Phase 2b Rolling Review trial in South with FDA going Africa reports on now. 55.4% efficacy against B1.351 Novavax is strain. Across hopeful to apply both trials 100% for EUA in May protection against using UK data, severe disease, otherwise EUA hospitalization, application will and death (here). occur summer 2021 when the US Phase III trial ends. MEDICAGO Plant produced Stable at 4-8 ᵒC 10 doses/vial 1 dose of Phase III trial Coronavirus-Like product + 1 began March 16, Particle COVID- Minimum order: dose of 2021 (here). 19 vaccine assume 100 adjuvant candidate doses Mixed on site (CoVLP) is composed of recombinant spike (S) glycoprotein expressed as -like particles (VLPs).

4

2 dose series 21 days apart INOVIO INO-4800 DNA Stable at 25 ᵒC for 10 doses/vial CELLECTRA Phase 1 data vaccine (2-dose >1 year, hand-held published on series) 37 ᵒC for >2 Minimum order: smart device June 30, 2020. months assume 100 uses electrical In buffer, 2-8 ᵒC doses pulse to deliver Phase II clinical for >5 years started Dec. 2020. FDA approval of CELLECTRA Phase III trial device began by the end continues to of the second delay start of quarter of 2021 PhaseII/III clinical trial Sanofi Pasteur + recombinant Storage 2-8 ᵒC for 10 doses of Recombinant Began Phase I/II 100 mil GlaxoSmithKline protein product and product/vial vaccine on Sept. 3, 2020. doses adjuvanted adjuvant 10 doses product + vaccine (2 dose adjuvant/vial adjuvant Disappointing + optional series) Administration: phase I/II results, purchase 25 ᵒC Minimum order: Mixed on site. Phase 2b trial of 500 mil assume 100 with modified doses doses vaccine product began February 22, 2021 (here). Sanofi Pasteur + mRNA vaccine Storage at -20 ᵒC Minimum order: Phase I/II trial TranslateBio MRT5500 assume 100 initiated March doses 12, 2021 (here). 1 or 2-dose series, 21 days apart being evaluated MERCK + IAVI DISCONTINUED (V590) MERCK #2 DISCONTINUED (V591)

5

Sources: • https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html • https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html • https://www.reuters.com/article/health-coronavirus-astrazeneca-vaccine/u-s-astrazeneca-vaccine-trial-will-clear-confusion-on-how-well-it- works-u-s-scientist-idUSKBN28H1YL • http://s23.q4cdn.com/479936946/files/doc_news/INOVIO-and-Advaccine-Announce-First-Dosing-of-Subject-in-Phase-2-Clinical-Trial-for- COVID-19-DNA-Vaccine-Candidate-INO-4800-in-China-2020.pdf • https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine- candidate/ • https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19 • https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval • https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf • https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-expects-to-begin-late-stage-covid-19-vaccine-study-in-second- quarter-idUSKBN2991HR • https://www.nytimes.com/2021/02/12/health/covid-vaccines-children.html • https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine • https://www.reuters.com/article/us-novavax-results/novavax-covid-19-shot-could-be-cleared-for-u-s-use-by-may-ceo-idUSKCN2AT3MD • https://www.reuters.com/article/us-health-coronavirus-astrazeneca-usa/exclusive-u-s-green-light-for-astrazeneca-vaccine-could-come-in- april-independent-monitors-assessing-data-us-official-idUSKBN2B723D

6